In prostate cancer, PDOs [23] with androgen receptor gene amplification were exquisitely and specifically sensitive to enzalutamide (androgen receptor antagonist), whereas those harboring both PTEN loss and PIK3R1 mutation were sensitive to PI3K pathway inhibitors (Everolimus and BKM-120). Here, AR is linked to prostate carcinoma.